本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ascendis Pharma A/S

174.96
-1.5300-0.87%
盘后174.960.00000.00%17:23 EDT
成交量:38.73万
成交额:6,787.28万
市值:105.95亿
市盈率:-27.80
高:177.18
开:176.42
低:173.78
收:176.49
数据加载中...
2020/05/08

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2020/04/03

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/01

财报披露

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/31

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/12

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/02/14

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/02/14

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/02/14

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/02/12

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/07

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/01/15

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/13

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/06

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/12

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/18

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/15

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/10/23

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/10/10

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]